Accera Completes $35 Million Series C Financing

Accera announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. The company says that the proceeds of this financing will be used to begin sales and marketing ofthe company’s lead product, Axona(TM) (previously known as Ketasyn), which as the company says, is [...]

TorreyPines Sells Alzheimer’s Disease Genetics Program to Eisai

TorreyPines Therapeutics, Inc. today announced that it has agreed to sell its Alzheimer’s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer’s disease genetics research [...]

GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal

GlaxoSmithKline Biologicals and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.
As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and [...]

Neuroptix Raises $18.5 Million in Successful B Round

Neuroptix Corporation has successfully raised a total of $18.5 million in its Series B funding round, as the company advances its diagnostic Alzheimer’s test toward clinical trials.
The investment, led by Inventages, will advance continued development of the Neuroptix Sapphire diagnostic platform and related technologies. The Neuroptix Sapphire system consists of a non-contact optical device combined [...]

Archer Pharmaceuticals Launches to Target Alzheimer’s Disease

This has to be the worst time in a decade to found a company.
Nobody told Michael Mullan and Fiona Crawford.
They’ve announced today that they have founded and incorporated Archer Pharmaceuticals to treat Alzheimer’s Disease.
Apparently, Archer has several compounds that are ready to enter clinical development, including ARC029 and ARC031. Both are targeted at the reduction [...]

Wyeth and Elan in a World of Pain

Image via Wikipedia
A little over a month ago, I wrote a post detailing how I thought the Bapineuzumab trial (which had just released phase 2 results) was a total loser.
It was, and still is, my contention that mAbs targeting APP, Tau, gamma secretase or the protein du jour in brain soup will not be effective [...]

Bapineuzumab Fails Trial

Image via Wikipedia

For a drug expected to top $7B in annual sales, even a partial success looks like a failure to me.  I’ve talked about the efficacy in modulating APP for the treatment of Alzheimer’s a few times and Derek Lowe @ has some great articles, so if you’re not familiar, I‘d check them out [...]